Annual report
2342.TEDINET S100W6FF
Period2024-04-01 → 2025-03-31
Filed2025-06-30
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amended by S100WG8Z (2025-08-01).
Key figures · 146
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥13.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥13.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥11.4bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥12.6bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥11.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | −¥260m | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Operating income | ¥89m | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Ordinary income | −¥320m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥108m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥199m | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.8bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥892m | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥676m | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥43m | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Net income (owners) | −¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥410m | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥1.9bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥546m | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Net income | ¥4m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Total assets | ¥9.6bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥9.8bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥10.7bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥10.4bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥8.9bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.7bn | at 2025-03-31 | Cons. | Liabilities |
| Total liabilities | ¥3.8bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥4.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥6.0bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥6.1bn | at 2023-03-31v | Cons. | Net assets |
| Net assets / equity | ¥6.6bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥5.0bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.6bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.5bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.5bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.5bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥3.5bn | at 2023-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.6bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥3.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥94m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥392m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥1.4bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.8bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥1.2bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥288m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥281m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥216m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥982m | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥48m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥265m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥343m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥485m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.2bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥10m | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-65.51 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥0.24 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-24.32 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥109.52 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥31.45 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥109.31 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥31.45 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥285.98 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥355.19 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥356.98 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥388.43 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥283.07 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 49.7% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 60.1% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 56.4% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.6% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 55.1% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 0.1% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 32.8% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 11.7% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 241 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 236 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 236 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 213 | at 2022-03-31v | Cons. | Number of employees |
| Employees | 248 | at 2021-03-31d | Cons. | Number of employees |
| Revenue | ¥287m | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥371m | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥397m | 2022-04-01 → 2023-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥365m | 2021-04-01 → 2022-03-31v | Standalone | Net sales (5-year summary) |
| Revenue | ¥377m | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | −¥20m | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Operating income | ¥73m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Ordinary income | −¥37m | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥87m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥73m | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥76m | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥32m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥1.1bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Profit before tax | −¥651m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Net income | −¥1.2bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | −¥662m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | −¥104m | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.7bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥180m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥6.4bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥6.9bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥8.0bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥7.6bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.7bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.8bn | at 2025-03-31 | Standalone | Liabilities |
| Total liabilities | ¥1.1bn | at 2024-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥4.7bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥5.9bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥6.7bn | at 2023-03-31v | Standalone | Net assets |
| Net assets / equity | ¥6.8bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥4.4bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥938m | at 2025-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.0bn | at 2024-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥-69.35 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-39.41 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-6.17 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥158.3 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥10.36 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥158 | 2021-04-01 → 2022-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥10.36 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥3 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥5 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥6 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥3 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥280.14 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥353.18 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥394.96 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥406.51 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥252.79 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 72.4% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.4% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.4% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 89.6% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 92.8% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 48.3% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.2% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 16,999,141 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 16,999,141 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 16,999,141 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,369,141 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,369,141 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 5 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 6 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 6 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 7 | at 2022-03-31v | Standalone | Number of employees |
| Employees | 25 | at 2021-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 58
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥1m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥1m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥6m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥6m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥2.8bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥210m |
| Drug Discovery Support Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥132m |
| Drug Discovery Support Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥102m |
| Drug Discovery Support Businessreportable segment | employees | at 2025-03-31 | 150 pure |
| Drug Discovery Support Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.9bn |
| Drug Discovery Support Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.9bn |
| Drug Discovery Support Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥6m |
| Drug Discovery Support Businessreportable segment | segment assets | at 2025-03-31 | ¥3.1bn |
| Drug Discovery Support Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | −¥488m |
| Investments And Consulting Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥135m |
| Investments And Consulting Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥36m |
| Investments And Consulting Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥11.1bn |
| Investments And Consulting Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥11.1bn |
| Investments And Consulting Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥438,000 |
| Investments And Consulting Businessreportable segment | segment assets | at 2025-03-31 | ¥3.6bn |
| Investments And Consulting Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥439m |
| TGBS Businessreportable segment | employees | at 2025-03-31 | 86 pure |
| —segment total | employees | at 2025-03-31 | 236 pure |
| Total Of Reportable Segments And Otherssegment total | capex | 2024-04-01 → 2025-03-31 | ¥267m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2024-04-01 → 2025-03-31 | ¥139m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2025-03-31 | ¥13.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2025-03-31 | ¥13.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥6m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2025-03-31 | ¥6.8bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2025-03-31 | −¥50m |
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥1m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥877,000 |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥7m |
| Reconciling Itemsreconciling | revenue external | 2023-04-01 → 2024-03-31 | ¥450,000 |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥7m |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥3.1bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥202m |
| Drug Discovery Support Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥254m |
| Drug Discovery Support Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥84m |
| Drug Discovery Support Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥2.3bn |
| Drug Discovery Support Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥2.3bn |
| Drug Discovery Support Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥6m |
| Drug Discovery Support Businessreportable segment | segment assets | at 2024-03-31 | ¥3.2bn |
| Drug Discovery Support Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥139m |
| Investments And Consulting Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥23m |
| Investments And Consulting Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥21m |
| Investments And Consulting Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥10.8bn |
| Investments And Consulting Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥10.8bn |
| Investments And Consulting Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥1m |
| Investments And Consulting Businessreportable segment | segment assets | at 2024-03-31 | ¥3.4bn |
| Investments And Consulting Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥430m |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥277m |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥105m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥13.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥13.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥7m |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥6.7bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥291m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,516
| Item | Context | Value | Unit |
|---|---|---|---|
| Average number of temporary workers | Prior4YearInstant_NonConsolidatedMember | － | |
| Average number of temporary workers | Prior3YearInstant_NonConsolidatedMember | － | |
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | － | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | － | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 1 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 2.210 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 1.497 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 1.193 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 0.890 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 0.690 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.421 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.450 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 1.534 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 2.168 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 2.134 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 150 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E05317-000DrugDiscoverySupportBusinessReportableSegmentsMember | 34 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E05317-000TGBSBusinessReportableSegmentsMember | 86 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E05317-000TGBSBusinessReportableSegmentsMember | 32 | |
| Number of employees | CurrentYearInstant_ReportableSegmentsMember | 236 | |
| Average number of temporary workers | CurrentYearInstant_ReportableSegmentsMember | 66 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 5 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 1 | |
| Number of employees | CurrentYearInstant | 241 | |
| Average number of temporary workers | CurrentYearInstant | 67 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 5 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 46.7 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 7.9 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 7003000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration | 83354000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 16999141 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 16999141 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 16999141 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 16999141 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 1 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 25 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 66 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 12 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 15 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 12080 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 12199 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 877 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 12346 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 6111 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 964 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 179 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 149430 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |